ClinicalTrials.gg
CompletedNCT07032493Updated Jun 11, 2026

Identifying the Limits of Survivability in Heat-exposed Older Females

An interventional study of Humidity-Ramp Protocol and Above-inflection fixed-condition exposure (5%) in Heat Stress, Temperature Change, Body and Aging, sponsored by University of Ottawa. Completed at 2 sites in Canada. Open to female participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Ottawa · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
Female
01

Study summary

Climate change increases extreme heat events, elevating global heat-illness risk. Females have reduced heat loss capacity (\~5%) compared to males, driven by differences in skin blood flow and sweating responses. While findings on sex-mediated mortality are mixed, some studies suggest older females (≥65 years), face higher heat-related mortality/morbidity risks, evidenced by disproportionate female deaths in the 2021 Western Heat Dome. The effects of extreme uncompensable heat on older females remain understudied.

Heat exposure initially causes net heat gain, raising core/skin temperatures and triggering heat-loss responses. Under compensable heat stress, heat loss balances gain, stabilizing core temperature. Uncompensable heat stress (exceeding maximal dissipation capacity) causes continuous core temperature rise, posing severe health risks. The specific temperature and relative humidity (RH) limits where compensability is lost are critical survival determinants, influenced by age and sex.

Ramping protocols identify these limits: participants face progressively increasing heat stress (e.g., staged humidity rises) while core temperature is monitored. Core temperature typically stabilizes initially, then exhibits an abrupt rapid increase at an inflection point, operationally defined as the limit of compensability. Despite increasing use, ramping protocol validity for accurately identifying this threshold remains unverified.

This project assesses ramping protocol validity for determining uncompensable conditions in older females and evaluates cumulative thermal and cardiovascular strain, as well as psychological and cognitive responses to both uncompensable and compensable heat. Participants will complete five trials. Trial 1 (Ramping): Rest at 42°C, 28% RH for 70min, then incremental RH increases (3% every 10min) to 70% RH. Individual core temperature (rectal) inflection points are identified from the ramping trial. Trials 2-5 (Fixed Conditions, Randomized): i) \~10% below inflection; ii) \~5% below inflection; iii) \~5% above inflection; iv) Thermo-neutral control (26°C, 45% RH). Comparing the rate of rectal temperature change and cumulative strain during prolonged fixed exposures (especially below vs. above inflection) will validate if the ramping inflection point represents the true limit of compensability for older females.

02

Conditions studied

  • Heat Stress
  • Temperature Change, Body
  • Aging
  • Thermoregulation
  • Heat Exposure

Keywords

  • heat strain
  • women
  • heat illness
  • Environmental limits for compensability
  • heat wave
  • hot weather
  • extreme heat events
03

In context

Heat Stress Disorders

118 studies on the registry are indexed under Heat Stress Disorders; 45 are open to participants now.

This study's enrollment of 12 is below the median of 24 across 104 interventional studies indexed under Heat Stress Disorders.

Browse Heat Stress Disorders studies →

Lead sponsor

University of Ottawa is the lead sponsor of 125 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking.
  • English or French speaking.
  • Ability to provide .
  • With or without a) chronic hypertension (elevated resting blood pressure; as defined by Heart and Stroke Canada and Hypertension Canada), b) type 2 diabetes as defined by Diabetes Canada, with at least 5 years having elapsed since time of diagnosis

Exclusion criteria

Exclusion Criteria:

  • Episode(s) of severe hypoglycemia (requiring the assistance of another person) within the previous year, or inability to sense hypoglycemia (hypoglycemia unawareness).
  • Serious complications related to diabetes (gastroparesis, renal disease, uncontrolled hypertension, severe autonomic neuropathy).
  • Uncontrolled hypertension - BP >150 mmHg systolic or >95 mmHg diastolic in a sitting position.
  • Restrictions in physical activity due to disease (e.g. intermittent claudication, renal impairment, active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis, etc.).
  • Use of or changes in medication judged by the patient or investigators to make participation in this study inadvisable.
  • Cardiac abnormalities identified during screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Other
    Humidity-ramp protocol

    The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Humidity-Ramp Protocol

  • Experimental
    Below-inflection fixed-condition heat exposure (5%)

    Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Below-inflection fixed-condition exposure (5%)

  • Active comparator
    Control fixed-condition heat exposure

    Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Control fixed-condition exposure

  • Experimental
    Below-inflection fixed-condition heat exposure (10%)

    Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Below-inflection fixed-condition exposure (10%)

  • Experimental
    Above-inflection fixed-condition heat exposure (5%)

    Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.

    Other: Above-inflection fixed-condition exposure (5%)

Interventions

  • OtherHumidity-Ramp Protocol

    Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which rectal temperature inflect is subsequently determined.

  • OtherAbove-inflection fixed-condition exposure (5%)

    After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' rectal esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.

  • OtherBelow-inflection fixed-condition exposure (5%)

    After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.

  • OtherBelow-inflection fixed-condition exposure (10%)

    After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~10% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.

  • OtherControl fixed-condition exposure

    Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.

06

What researchers measure

Primary outcomes

  1. Rectal temperature rate of change

    Rate of change of rectal temperature measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

Secondary outcomes

  1. Number of participants unable to finish fixed-condition heat exposure

    Number of participants who could not complete each fixed-condition heat exposure due to participant withdrawal or achieving a core temperature of 39.5°C

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  2. Mean skin temperature rate of change

    Rate of change of skin temperature measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  3. Core temperature (AUC)

    Area under the curve (AUC) of rectal temperature (in degree-hours) measured over the fixed-condition heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  4. Predicted time until 40.2°C esophageal temperature

    Estimated time for rectal temperature to reach 40.2°C, a commonly-cited criteria for severe heat-illness (e.g., heat stroke), calculated from the end-exposure rectal temperature and its rate of change (assuming this rate of change is sustained)

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  5. Heart rate rate of change

    Rate of change of heart rate measured over the final 2-hours of heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  6. Heart rate (AUC)

    Area under the curve (AUC) of heart rate measured over the fixed-condition heat exposure

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  7. Thermal sensation

    Self-reported thermal sensation at the end of the fixed-condition exposures using and 8-point scale ranging from neutral (0) to extremely hot (8).

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  8. Thermal comfort

    Thermal comfort assessed via a visual analog scale ranging from extremely uncomfortable to extremely comfortable (midpoint: neutral).

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  9. Sweat rate

    Sweat rate at the end of the fixed-condition exposures (calculated via change in body weight)

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  10. Net fluid loss

    Net fluid loss estimated as the percentage change in body mass over the fixed-condition exposures.

    Time frame: End of fixed-condition heat exposure (hour 9 or termination)

  11. Profiles of Mood States (POMS)

    Potential changes in mood (7 subscales of mood: tension, anger, depression, fatigue, confusion, vigor and esteem-related affect). The POMS-40 is a validated, self-administered questionnaire that examines seven distinct aspects of mood state across two positive subscales (Esteem-Related Affect, and Vigor) and five negative subscales (Fatigue, Tension, Confusion, Anger, and Depression), which are described across 40 distinct adjectives (reference). For each individual item, participants were asked to describe "how you feel right now" by responding using a 5-point Likert scale (0 = "Not at all", 1 = "A little", 2 = "Moderately", 3 = "Quite a lot", or 4 = "Extremely"). The values of items associated with a specific subscale (e.g., Fatigue) were summed to calculate its score.

    Time frame: Prior to (hour 0) and at the end of fixed-condition heat exposure (hour 9 or termination)

  12. Environmental Symptoms Questionnaire (ESQ)

    Self-reported environmental reactions and medical symptomatology associated with prolonged heat exposure. The ESQ-IV is a validated 68-item, self-administered questionnaire that has been used successfully in identifying symptomatology during exposure to a wide variety of environmental conditions, including heat exposure \[24, 25\]. Participants are asked to assess and described "how you have been feeling today" by responding to each item using a 6-point Likert scale (0 = "Not at all", 1 = "Slight", 2 = "Somewhat", 3 = "Moderate", 4 = "Quite a bit", or 5 = "Extreme"). Total Symptom Score was calculated from this data by taking the sum of the intensity ratings from all 68 individual items using reverse scores for the three positive items from the list ("I Felt Good", "I Felt Alert", and "I Felt Wide Awake").

    Time frame: Prior to (hour 0) and at the end of fixed-condition heat exposure (hour 9 or termination)

Other outcomes

  1. Rectal temperature inflection point

    Inflection point for rectal temperature during the humidity-ramp protocol

    Time frame: During the ramp protocol (up to 2.5 hours)

  2. Heart rate inflection point

    Inflection point for heart rate during the humidity-ramp protocol

    Time frame: During the ramp protocol (up to 2.5 hours)

07

Study locations

2 sites
  • University of Ottawa
    Ottawa, Ontario K1N6N5, Canada
  • University of Ottawa
    Ottawa, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant data will be made available upon reasonable request and signed access agreement.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be made available following publication of the primary study report.

Access criteria: Reasonable request and signed access agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in May 2026, 9 months.

Of 75 non-industry interventional studies with no phase under Heat Stress Disorders, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 9 months is below that.

Counting every sponsor, half of 75 studies reached it within 16 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2025
First posted
Jun 24, 2025
StartActual
Jul 16, 2025
Primary completionActual
May 1, 2026
CompletionActual
May 1, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07032493
Responsible party
Glen P. Kenny (Full Professor, University of Ottawa) — Principal investigator
First posted
Jun 24, 2025
Start date
Jul 16, 2025
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Jun 11, 2026

Study contacts

Glen P Kenny, PhD
principal investigator · University of Ottawa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion